Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.66 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NPBWR1 | P48145 | 5/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11785004 | 0.84 | RAB9A (0.67) | RAB9ANPC1PAX8SMN1; SMN2CYP1A2 | |
| SCHEMBL3033865 | 0.82 | NPC1 (0.66) | RAB9ANPC1PAX8SMN1; SMN2CYP1A2 | |
| SCHEMBL3031931 | 0.80 | NPC1 (1.00) | RAB9ANPC1PAX8SMN1; SMN2CYP1A2 | |
| SCHEMBL18446084 | 0.80 | RAB9A (0.78) | RAB9ANPC1PAX8SMN1; SMN2CYP1A2 | |
| SCHEMBL31277650 | 0.80 | NPC1 (1.00) | RAB9ANPC1PAX8SMN1; SMN2CYP1A2 | |
| SCHEMBL18445806 | 0.78 | RAB9A (0.74) | RAB9ANPC1PAX8SMN1; SMN2CYP1A2 | |
| SCHEMBL3028307 | 0.78 | RAB9A (0.66) | RAB9ANPC1PAX8SMN1; SMN2LMNA | |
| SCHEMBL13219325 | 0.75 | RAB9A (0.71) | RAB9ANPC1PAX8SMN1; SMN2LMNA | |
| SCHEMBL17057835 | 0.73 | GRM1 (0.43) | RAB9ANPC1PAX8SMN1; SMN2CYP3A4 | |
| SCHEMBL11729328 | 0.73 | RAB9A (0.54) | RAB9ANPC1PAX8SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2518063-B1 | Pyridazinones and furan-containing compounds | SLOAN-KETTERING INST FOR CANCER RES (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2518063-B1 | Pyridazinones and furan-containing compounds | SLOAN-KETTERING INST FOR CANCER RES (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2099770-B1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN KETTERING INST CANCER (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2099770-B1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN KETTERING INST CANCER (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2008080056-A2 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008080056-A2 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080121640-A1 | DISPOSABLE CASSETTE FOR INCREMENTAL WITHDRAWAL OF TUBULAR PLASTIC WITH MALODOR-COUNTERACTANT CAPACITY | EVEREADY BATTERY COMPANY, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20060249418-A1 | Odor transmission-resistant polymeric film | PLAYTEX PRODUCTS, INC. | 2006-11-09 | — | — | US | disclosed |
| US-7100767-B2 | Odor transmission-resistant polymeric film | PLAYTEX PRODUCTS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1497111-A1 | ODOR TRANSMISSION-RESISTANT POLYMERIC FILM | PLAYTEX PRODUCTS, INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20030218022-A1 | Odor transmission-resistant polymeric film | BANK OF MONTREAL (CA) | 2003-11-27 | — | — | US | disclosed |
| US-20030213804-A1 | Disposable cassette for incremental withdrawal of tubular plastic with malodor-counteractant capacity | PLAYTEX PRODUCTS, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003089312-A2 | DISPOSABLE CASSETTE FOR INCREMENTAL WITHDRAWAL OF TUBULAR PLASTIC WITH MALODOR-COUNTERACTANT CAPACITY | PLAYTEX PRODUCTS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003089230-A1 | ODOR TRANSMISSION-RESISTANT POLYMERIC FILM | PLAYTEX PRODUCTS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | RAB9A 3655/4885NPC1 2857/4885PAX8 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.